Targeting oncogenic gαq/11 in uveal melanoma

Dominic Lapadula  
*Thomas Jefferson University*

Jeffrey L Benovic  
*Thomas Jefferson University*

Follow this and additional works at: https://jdc.jefferson.edu/bmpfp

Part of the Medical Biochemistry Commons, and the Medical Molecular Biology Commons

Let us know how access to this document benefits you

**Recommended Citation**

Lapadula, Dominic and Benovic, Jeffrey L, "Targeting oncogenic gαq/11 in uveal melanoma" (2021). *Department of Biochemistry and Molecular Biology Faculty Papers*. Paper 200.  
https://jdc.jefferson.edu/bmpfp/200

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Biochemistry and Molecular Biology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Review

Targeting Oncogenic Gαq/11 in Uveal Melanoma

Dominic Lapadula and Jeffrey L. Benovic *

Department of Biochemistry and Molecular Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA; dominic.lapadula@students.jefferson.edu
* Correspondence: jeffrey.benovic@jefferson.edu; Tel.: +1-215-503-4607

Simple Summary: Uveal melanoma is a deadly form of eye cancer with a high rate of metastasis. Once metastasis occurs, patients are often left with a short survival time, since there is no FDA standard of care for the metastatic disease. Uveal melanoma develops from mutations mainly in proteins involved in the Gq/11 signaling pathway, which drives pathogenesis. This review article aims to summarize pre-clinical and clinical studies that have attempted to understand and treat the disease by inhibiting the Gq/11 signaling pathway. We discuss the limited success of treatments focused on downstream targets of the Gq/11 Pathway and evaluate the effectiveness and feasibility of treating the disease by directly inhibiting Gq/11.

Abstract: Uveal melanoma is the most common intraocular cancer in adults and arises from the transformation of melanocytes in the uveal tract. While treatment of the primary tumor is often effective, 36–50% of patients develop metastatic disease primarily to the liver. While various strategies have been used to treat the metastatic disease, there remain no effective treatments that improve survival. Significant insight has been gained into the pathways that are altered in uveal melanoma, with mutually exclusive activating mutations in the GNAQ and GNA11 genes being found in over 90% of patients. These genes encode the alpha subunits of the heterotrimeric G proteins, Gq and G11, and mutations result in activation of several important signaling pathways, including phospholipase C and activation of the transcription factor YAP. In this review, we discuss current efforts to target various signaling pathways in the treatment of uveal melanoma including recent efforts to target Gq and G11 in mouse models. While selective targeting of Gq and G11 provides a potential therapeutic strategy to treat uveal melanoma, it is evident that improved inhibitors and methods of delivery are needed.

Keywords: cancer; G proteins; metastasis; signaling; uveal melanoma

1. Introduction

Uveal melanoma (UM) is the most common intraocular tumor in adults, and, as the second most common form of melanoma, accounts for approximately 5% of all melanomas. The median age at diagnosis is about 62 years, and risk factors include fair skin, light eye color (green or blue), ocular melanocytosis, dysplastic nevus syndrome, germline BRCA1-associated protein 1 (BAP1) mutations, and welding as an occupation [1–5]. UM arises from melanocytes contained in the choroid, ciliary body, and iris (together known as the uvea) of the ocular cavity, and has a high propensity to metastasize [6,7]. As a result, 36–50% of patients with UM develop metastasis, predominantly to the liver, even when the primary tumor has successfully been eliminated [3,6,8–11]. While the primary tumor can be successfully treated via enucleation, laser therapy, radiotherapy, or surgical resection, many experts believe that the metastatic spread of UM is unpreventable, as it has likely already taken place by the time the primary tumor is detected [8]. For instance, only 4% of patients show detectable metastasis at the time of diagnosis of the primary tumor, but up to half of all UM patients will develop metastatic disease. This suggests UM develops small, undetectable metastases at an early stage of tumorigenesis, as early as 5 years
prior to primary tumor detection, that remain dormant or quiescent for years, classifying UM as a systemic disease requiring some form of systemic therapy [12–14]. Once macro-metastasis develops, patients have a poor prognosis with a median overall survival time of less than 1 year as there are currently no effective therapies with a significant impact on survival [6,15–19].

To date, there is no FDA standard of care for metastatic UM. Systemic treatments that have been successful in treating cutaneous melanoma (CM), such as chemotherapy and immunotherapy, have largely failed to produce similar positive results in UM patients. UM response rates to chemotherapy drugs such as dacarbazine, temozolomide, cisplatin, treosulfan, and fotemustine range from 0% to 15%, and no agent has successfully prolonged survival [20–24]. Moreover, immune checkpoint inhibitors of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death-1 (PD-1), which significantly improve survival outcomes for patients with advanced CM, have shown no clinical benefit in patients with metastatic UM [25–28]. Additionally, while BRAF inhibitors show efficacy in treating CM patients, UM remains unresponsive to similar treatments, despite both malignancies originating from melanocytes derived from the neural-crest [7,29]. These differences may be explained by the observation that UM has a distinctly different etiology from CM. The main oncogenic BRAF and NRAS driver mutations in CM are not typically found in UM [30–34], and while 80% of CM show a UV radiation mutational signature, there is no observed evidence of the same in UM [26,35]. Furthermore, UM has an incredibly low mutational burden compared to CM and most other cancer types [36,37]. With an improved understanding of the genetic differences between cutaneous melanoma and uveal melanoma, there is a clear need for more specific or targeted treatment strategies for UM, as advances in CM treatment will be unlikely to confer the same results in UM.

2. Driver Mutations Involved in UM

UM predominantly involves mutually exclusive activating mutations in the GNAQ or GNA11 genes that encode the highly conserved Gαq and Gα11 subunits of the heterotrimeric G-proteins [31,38,39]. The introduction of the oncogenic Gαq/11 mutants into human or mouse melanocytes results in anchorage-independent growth and gives rise to heavily pigmented tumors in mice [39–41]. Interestingly, while about 93% of cases contain oncogenic Gαq or Gα11, cases without such mutations often harbor activating mutations in other genes linked to the Gq pathway. Activating mutations in PLCB4, which encodes for the canonical Gq effector phospholipase C β (PLCβ), or Cysteinyl Leukotriene Receptor 2 (CYSLTR2), a G protein-coupled receptor (GPCR) activator of Gq, are observed in 2.5% and 4% of cases, respectively [26,36,42,43]. Taken together, it has become clear that aberrant signaling via the Gq pathway is the main driver of uveal melanoma.

3. Gαq/11 Proteins and Their Mutations in UM

Gαq and Gα11 proteins are members of the Gq subfamily of Gα proteins, are 90% homologous at the amino acid level, and are ubiquitously expressed. To maintain homeostasis in mammalian cells, the activation and deactivation of G-proteins is regulated by tight control over GDP/GTP exchange and GTP hydrolysis rates. Ligand-activated GPCRs, such as CysLTR2, act as guanine nucleotide exchange factors (GEFs) by stimulating the exchange of GDP for GTP on the Gα subunit of the heterotrimeric G-protein. Upon binding to GTP, the Gα subunit changes conformation, dissociates from the Gβγ dimer, and interacts with downstream effectors, such as PLCβ and ARF6 [44–49]. Gα proteins contain a Ras-like GTPase domain, wherein important amino acid residues provide the subunit with intrinsic GTP hydrolytic activity, which is accelerated by the interaction of GTPase-activating proteins (GAPs), such as regulators of G protein signaling (RGS). GTP hydrolysis to GDP then terminates the Gα signaling, allowing the subunit to reassociate with Gβγ and return to an inactive state [44,50,51].

The Gαq/11 mutations observed in uveal melanoma primarily occur at the Q209 and R183 residues [31,38,39]. Both mutational hotspots are in the GTPase domain and are critical
for stabilizing the transition state for GTP hydrolysis. When mutated, the protein loses its GTPase activity and is rendered constitutively active in the GTP-bound state, leading to aberrant proliferative signaling [38,39,47,52–54]. Q209 mutations (Gαq/11Q209L/P) are 13 times more frequent than R183 mutations (Gαq/11R183C) in UM. While Q209 mutations effectively impede GTPase activity, R183 mutants still retain the ability to hydrolyze GTP, although at a reduced catalytic rate, through interactions with RGS proteins, and still respond to receptor stimulation [39,50,55]. Since Gαq/11Q209 mutants appear incapable of hydrolyzing GTP even in the presence of RGS proteins, aberrant signaling is increased, leading to a more severe phenotype [52].

4. Inhibition of Signaling Pathways Downstream of Activated Gαq/11

Due to the redundancy of their signaling pathways, oncogenic mutations in either Gαq or Gα11 appear to cause similar cellular oncogenic properties leading to the pathogenesis of UM (Figure 1). For example, GNAQ and GNA11 mutations are responsible for the upregulation of mitogen-activated protein kinase (MAPK) pathway, RAF/MEK/ERK, in the absence of BRAF mutations in UM [30,56–58]. Knockdown of Gαq in cell lines derived from primary or metastatic UM results in decreased MAPK signaling [38]. Additional Gαq/11 stimulated signaling pathways that promote tumorigenesis have been implicated in UM. Oncogenic Gαq/11 leads to aberrant Akt signaling through PI3K/AKT/MTOR and increased activation of small GTPases RhoA and Rac1, which promote cell growth through JNK, p38, and yes-associated protein (YAP)-directed transcription of growth promoting genes [40,41,59–61]. To date, most of the efforts to treat UM have mainly been focused on inhibiting the downstream signaling pathways of oncogenic Gαq/11 and have provided limited success in improving progression-free survival of UM patients.

![Figure 1. Signaling Pathways in Uveal Melanoma. Activating mutations in GPCR CysLTR2, Gαq/11, and PLCβ4 stimulate downstream signaling pathways such as ARF6, MAPK, FAK/YAP, and AKT/MTOR, all of which can lead to UM cell proliferation and survival.](image-url)
4.1. ARF6 Inhibition

ADP-ribosylation factor 6 (ARF6) is a small G-protein that has been shown to be an immediate downstream effector of an activated GNAQ/GEP100 complex. ARF6 acts as a proximal node of G\(\alpha_q\) signaling to induce all the downstream pathways as well as \(\beta\)-catenin signaling. ARF6 mediates the trafficking of G\(\alpha_q\) from the cell membrane to cytoplasmic vesicles and \(\beta\)-catenin to the nucleus. Inhibition of ARF6, by the ARF6 specific small-molecule inhibitor, NAV-2729, reduces uveal melanoma cell proliferation and tumorigenesis in a mouse model [48]. Therefore, ARF6 is considered a potential therapeutic target downstream of oncogenic G\(\alpha_q\).

4.2. PKC Inhibition

Activated G\(\alpha_q\) canonically triggers the protein kinase C (PKC) pathway through diacylglycerol produced by PLC\(\beta\) activation [44]. Attempts to inhibit PKC in UM have shown promise. The pan-PKC inhibitor, AEB071 (sotrastaurin), at low micromolar concentrations, significantly inhibits the growth of UM cells harboring GNAQ mutations, through G1 arrest and apoptosis, and had little effect on UM cells carrying wild-type GNAQ [62]. A phase one study of AEB071 resulted in one achieved partial response, while 47% of 118 participants achieved disease stabilization and a median progression-free survival of 15.4 weeks although with some adverse effects [63]. This suggests there is some clinical benefit of PKC inhibition and a new phase one study using the PKC inhibitor LXS196 is currently underway (NCT02601378).

While PKC inhibitors inhibit MAPK signaling and induce G1 arrest in UM cells, they fail to induce tumor regression in xenograft models. As a result, combination treatments of PKC and MEK inhibitors have been attempted and have shown synergistic effects on tumor regression in a UM in vivo model [64]. However, a phase one-b/two study of a PKC and MEK combination treatment of patients with metastatic UM was halted before the beginning of phase two (NCT01801358).

4.3. MAPK Pathway Inhibition

The drugs that have been used most often in an attempt to inhibit downstream G\(\alpha_q/11\) signaling in UM are MEK inhibitors, because, similar to CM, MAPK signaling levels are elevated in most UM [57]. Early studies showed MEK inhibitors, such as selumetinib or TAK-733, successfully inhibit UM cell proliferation and viability in vitro [65]. These studies resulted in several clinical trials with various MEK inhibitors, the first of which was a comparison of selumetinib versus chemotherapy treatment, which showed improved progression-free survival (15.9 vs. 7 weeks) but did not significantly improve overall survival (9.1 vs. 11.8 months), while treatment-related adverse events were observed in 97% of patients treated with selumetinib [66]. There is currently recruitment for a new phase one trial to test the effect of intermittent selumetinib administration. The purpose of this study is to test higher drug doses, to more completely block the MAPK pathway and prevent the development of drug resistance mechanisms within the tumor. Intermittent administration of the drug may also reduce side effects (NCT02768766). A phase one study using TAK-733 also showed limited antitumor activity in patients with advanced solid tumors [67].

A recent review analyzed 590 case records from six eligible clinical trials, including the study mentioned above [66]; a phase three study of selumetinib in combination with dacarbazine [68]; phase two studies of selumetinib monotherapy versus temozolomide [69], as well as trametinib, with or without GSK2141795 [70]; a phase one study of trametinib [71]; and a terminated phase one study of AEB071 and MEK162 (NCT01801358). The conclusion is that UM is poorly responsive to MEK inhibitors, regardless of the inhibiting agent and combination partner [72]. The failure of MEK inhibitors to provide meaningful effects on overall survival and tumor growth may be explained by resistance mechanisms that are enabled by the growth factors present in the liver tumor microenvironment [73,74]. However, these results have not deterred investigators from continuing to search for effective combinations with selumetinib. A preclinical study of selumetinib in combination...
with the ERK inhibitor AZ6197, or the mTORC1/2 inhibitor AZD2014, displayed significant efficacy in two PDX mouse models of UM [75]. Another recent study suggests chloroquine or hydroxychloroquine sensitizes GNAQ/11-mutant UM to MEK inhibition by trametinib, through the inhibition of autophagy or lysosome function. This combination treatment synergistically inhibited tumor growth in metastatic mouse models [76].

While MAPK signaling is significantly upregulated in UM, and is often the target of potential therapeutic interventions, the mechanism of how oncogenic G\(^\alpha_q/11\) activates the MAPK pathway is incompletely understood. The Ras guanyl releasing protein (RASGRF3) is highly expressed in G\(^\alpha_q/11\)-driven tumors, acts as a critical node for ERK activation, and is activated via the PKC\(\delta\) and \(\epsilon\)-isomers downstream of activated G\(^\alpha_q/11\) in UM [77,78]. RASGRF3 is required for growth and Ras-MAPK activation in UM cells, as knockdown of the gene transcript leads to decreased MAPK signaling and reduced growth in vitro and in vivo [77,78]. Therefore, RASGRF3 is considered a potential therapeutic target downstream of G\(^\alpha_q/11\) and represents an additional avenue to MAPK inhibition specific to UM.

### 4.4. PI3K/AKT/MTOR Inhibition

Another activated pathway downstream of oncogenic G\(^\alpha_q/11\) that has been therapeutically targeted is the PI3K/AKT/MTOR pathway. This pathway is often targeted in combination with MEK or PKC inhibition. One study showed that neither MEK nor PI3K inhibition by trametinib or GSK2126458 alone was sufficient to induce apoptosis in the majority of UM cell lines, but the combination of MEK and PI3K inhibitor treatment resulted in a significant induction of apoptosis in a GNAQ/11 mutant-dependent manner [79]. Another study co-targeted PI3K and PKC inhibition with BYL719 and AEB071, which showed synergistic inhibition of cell proliferation and apoptotic cell death in UM cells, as well as a significant reduction in tumor growth, in a xenograft model [80]. As a result, a phase one clinical trial of the efficacy and safety of BYL719 and AEB071 drug combination in metastatic UM has begun, but its status is unknown (NCT02273219). Others have targeted AKT in combination with MEK inhibition, which showed induced activation of AMP-activated protein kinase, resulted in the synergistic induction of autophagic cell death in UM cells, and inhibited UM tumor growth in xenograft mouse models [81]. This evidence led to a phase two clinical trial, mentioned previously [70], of trametinib with or without the AKT inhibitor GSK2995, which failed to improve progression-free survival compared to selumetinib treatment alone. Additionally, MTOR has also been targeted in UM studies. A phase two clinical trial tested the combination of the MTOR inhibitor everolimus, and the somatostatin receptor agonist pasireotide, in metastatic UM patients. The combination showed little benefit and significant side-effects [82]. A preclinical study found some success in the combination treatment of the MTOR inhibitor everolimus and the PI3K inhibitor GDC0941, which provided increased apoptosis in UM tumors in two PDX models [83]. Another study showed synergistic effects on tumor regression in UM PDX models with a combination of the mTORC1 inhibitor RAD001 and the PKC inhibitor AEB071 [84].

### 4.5. YAP Inhibition

The upregulation of yes-associated protein (YAP) driven by oncogenic G\(^\alpha_q/11\) in UM is a recent observation [40,41,85]. YAP is a co-transcriptional regulator involved in the cell-growth-regulating Hippo pathway, which, when dephosphorylated, translocates from the cytoplasm into the nucleus, where it associates with TEA domain transcription factor (TEAD) to promote the transcription of growth promoting genes [86–89]. Studies have shown that knockdown of G\(^\alpha_q/11\) inactivates YAP, while YAP is required for mutant G\(^\alpha_q/11\) driven tumorigenesis [40,41]. Further studies indicated that YAP dephosphorylation in UM occurs through the G\(^\alpha_q/11\) activation of Trio, a guanine nucleotide exchange factor for the small G-proteins, RhoA and Rac1, independent of the Hippo pathway [41]. Additionally, the YAP inhibitor, verteporfin, can inhibit oncogenic G\(^\alpha_q/11\) UM cell growth
in mice [40,41,90]. Although these original studies suggest YAP as a potential therapeutic target of UM, there has since been conflicting studies that suggest YAP may not be as crucial to UM tumorigenesis as originally thought. One study investigating the association between YAP activity and clinical outcome concluded that the effect of YAP on the development, growth, and invasion of UM in patients is less than previously found in experimental studies [91]. Another study investigated the susceptibility of melanoma cell lines to YAP inhibition by verteporfin and found that while most UM cell lines responded in vitro to verteporfin, high-risk metastatic UM lines (BAP1-negative) did not. Therefore, the mutational background is an important predictor of response to YAP inhibition by verteporfin, suggesting that not all UM cell lines are susceptible to YAP inhibition [92].

4.6. FAK Inhibition

Related to the Hippo pathway and YAP signaling, a recent study showed that Gaq activates focal adhesion kinase (FAK), and that FAK activity is essential for YAP activation and UM cell growth. Using an integrated bioinformatics pipeline, FAK was identified as a candidate synthetic lethal gene with GNAQ activation. FAK inhibition, by small molecules VS-4718 or PF562771, suppresses YAP activation in vivo and prevents UM cell growth [93]. Unfortunately, MAPK signaling via oncogenic Gaq provides resistance to FAK inhibition in UM cells. Therefore, a study wherein UM cells were treated with a combination of the MEK inhibitor trametinib and the FAK inhibitor VS-4718 showed a synergistic effect on metastatic UM tumor growth in a mouse model [94]. This study led to a phase two clinical trial, which is currently recruiting metastatic UM patients, testing the efficacy of the combination treatment of the RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib (VS-6063) (NCT04720417). Another recent study suggests that PLCb/PKC activity, but not FAK/YAP, is elevated in UM cell lines as a consequence of Gaq pathway mutations, and that FAK may not be activated independent of PLCb activation, as previously suggested [95]. This study further illustrates that PKC/MAPK signaling is essential for UM cell proliferation, and that only combined inhibition of PKC and MEK, not FAK and MEK, or FAK and PKC, synergistically reduces cell viability in UM cells [95]. However, this was only shown in a few UM cell lines, and may not be true in every instance of UM, as there is evidence to the contrary, as previously discussed. However, this study, along with the observation that genetic analyses of UM have failed to identify mutations in the FAK or YAP pathways, suggest that FAK or YAP may not be optimal targets for therapeutic intervention in UM [26,96].

5. Direct Targeting of Gaq/11

Taken altogether, a potential explanation for these unsuccessful therapies is that oncogenic Gaq/11 activates multiple, individually dispensable downstream signaling networks. Inhibition of one, or sometimes two, pathways does not achieve the desired treatment outcome. This raises the possibility that direct inhibition of oncogenic Gaq/11 may be an advantageous and promising therapeutic strategy for UM treatment. While there are no current FDA-approved drugs that directly target Gaq/11, a few compounds, namely YM-254890 (YM) and FR900359 (FR) (Figure 2), that effectively inhibit Gaq/11, have been identified and have shown some promising results in pre-clinical UM studies [97,98].
Figure 2. Chemical structures of Gq/11 depsipeptide inhibitors YM-254890 and FR900359. Highlighted areas show the regions of YM-254890 and FR900359 that differ.

5.1. Short History of Gq Inhibitors

YM is a cyclic depsipeptide first isolated from Chromobacterium sp. QS3666 in 2003 during a screen for platelet aggregation inhibitors of human plasma [99]. After its isolation, YM was found to reduce the mobilization of intracellular Ca\(^{2+}\) by selective inhibition of the G\(_q\), G\(_{11}\), and G\(_{14}\) proteins, without affecting the signaling of other G-proteins [55]. G\(_q\) inhibition by YM was then used as a pharmacological tool to probe G\(_q\) signaling in cells and mice. Originally it was determined that YM inhibits ADP-induced platelet aggregation (a G\(_q\)-mediated biological response) in vitro, followed by studies that showed that it prevents the formation of thrombosis and neointima in rats and monkeys, and demonstrates antithrombotic and thrombolytic activity [99–102].

Unfortunately, shortly after its discovery, YM became unavailable to researchers, and in 2012 a worldwide competition for the total synthesis of 1 mg of YM was announced. Due to its complex macrocyclic structure, the total synthesis of YM is not a simple task, but in 2016 the first total synthesis of YM and FR was achieved, albeit with a very low yield [103]. Shortly thereafter, YM became commercially available.

FR, also known as UBO-QIC, is structurally very similar to YM and only differs by the addition of three methyl groups. It was first isolated from the plant Ardisia crenata sims in 1988 during an investigation into possible platelet aggregation inhibitors [104]. It has since been shown that FR is synthesized by Candidatus Burkholderia crenata, a bacterial symbiont of Ardisia crenata Sims [105]. FR is a potent and selective inhibitor of G\(_{\alpha_q11/14}\), has a vasorelaxant effect in rats, and effectively inhibits agonist-promoted airway contraction in human precision-cut lung slices and rats [106–109]. FR has also been suggested to inhibit G\(\beta\gamma\) signaling following the activation of G\(_i\)-coupled receptors [110], although this effect may be due to the involvement of G\(_{\alpha_q}\) in G\(\beta\gamma\)-mediated activation of PLC\(\beta\) [111].

FR was commercially available for a short period of time from the König group at the University of Bonn, who isolated it from the dried leaves of A. crenata Sims, but the compound is no longer sold. The König group has managed to biosynthesize FR in cultivable E. coli by expression of the FR nonribosomal peptide synthetase (frs) genes, which are found in Candidatus Burkholderia crenata and are responsible for the production of FR in the endosymbiont [112]. The Wollbrett group sought to improve upon the low yield of FR by this method via genetic engineering of Chromobacterium vaccinii DSM 25,150, with some success [113]. However, chemical synthesis and biosynthesis methods result in very low yields, leaving purification of the compound from natural sources as the main method of production, as is the case for YM.
5.2. Mechanism of Action and Physiochemical Properties of YM and FR

In 2010, the structural basis for inhibition was revealed via an X-ray co-crystal structure of YM bound to a chimeric Gαq/βγ protein complex, showing that YM acts as a guanosine nucleotide dissociation inhibitor (GDI) [114]. The structure revealed that YM binds to a hydrophobic pocket between linker one and switch I of the Gαq subunit, with minimal contact with Gβγ. The region in which linker one and switch I reside is between the helical and GTPase domains and undergoes large conformational changes between the inactive GDP-bound and active GTP-bound conformations. Upon binding of YM, the GDP-bound state of Gαq is stabilized by suppression of the hinge motion of linker one and switch I, resulting in the inhibition of the GDP/GTP exchange, leaving the Gαq protein “locked” in the GDP-bound, inactive conformation [114].

In an effort to characterize FR, a comprehensive 2015 study used molecular dynamics simulations, and a combination of purified proteins and cell-based assays, to show that FR functions similarly to YM as a GDI of Gαq/11/14 proteins [107]. This same study determined that FR inhibits Gαq activation in a pseudo-reversible manner, and that its effects are exceptionally resistant to washout in vasorelaxation and cell-based experiments. Mutagenesis studies established that FR and YM bind to the same hydrophobic pocket of Gαq, and that genetically engineered FR-binding sites can be used to create additional Gα proteins, susceptible to FR inhibition, as an investigatory tool [115].

While YM and FR are very similar in their structure and mechanism of action, they do show some biologically distinct activities. FR inhibits Gαq/11 with a 3-fold higher potency than YM, and disruption of FR binding to Gαq is more difficult to achieve than the binding of YM [103,115]. This difference in potency may be explained by physiochemical, kinetic, and molecular characteristics that the two very similar compounds do not share. As explained previously, FR differs from YM by the addition of three methyl groups. These differences make FR slightly larger and more lipophilic than YM. A conformational study showed that while FR exists as a single conformer in aqueous solution, YM exists as two different conformers in a major–minor (3:1) ratio. The major form is the biologically active conformer, while the minor represents a conformer that is unable to inhibit Gαq [116]. This suggests that conformational stability is important to the inhibitory potency of these compounds. Additionally, while both compounds display similar association rates (t1/2(FR) = 3.6 min versus t1/2(YM) = 8.8 min), FR binds pseudo-reversibly and displays a residence time of 92.1 min, compared to 3.8 min for YM [117]. Molecular docking studies seeking to explain this difference in dissociation rates suggest the additional lipophilic moieties of FR anchor the compound in the binding pocket, similar to “a dowel forming a latch”, while YM lacks those anchor points and may be more readily released from the Gq protein [117]. This suggests that even small changes, which seem insignificant within such a large and complex molecule, can lead to differences in potency and potential pharmacological effects.

5.3. YM and FR Activity in Uveal Melanoma

Since the discovery of YM and FR, as potent Gαq/11 inhibitors, it was believed that the two compounds could inhibit only wild-type and R183 mutant proteins, but not Q209 mutants, which are almost always the driver mutations in UM. For example, the inhibitory effect of YM on Gαq Q209L and R183C mutants was first tested in HEK293 cells, co-transfected with a serum response element (SRE)-luciferase reporter gene, and either Gαq Q209L or R183C mutant cDNA. This study showed the constitutive activity of the R183C mutant to be completely suppressed by YM, while that of the Q209L mutant was only modestly affected [55]. A comprehensive characterization of FR as a Gαq/11/14 selective inhibitor found that it was capable of inhibiting the Q209 mutant Gαq/11 [107]. In this study, FR inhibited the growth of a mouse melanoma cell line, Hcmel12, which carries a Gαq-Q209L mutation, and is wild type for B-Raf and N-Ras. FR was also found to effectively inhibit nucleotide binding to purified Gαq-Q209L protein in vitro, suggesting FR directly binds to the mutant Gαq/11 [118]. FR also inhibited the growth and proliferative signaling
of UM cells containing oncogenic Gαq/11 proteins [118]. Additional studies investigating similar effects of FR emerged around the same time [93,119–121] while research involving YM treatment of UM have followed [95,122].

YM and FR show significant inhibitory activity against every mutant Gαq/11 variant found in UM in transfected HEK293 cell-based experiments [121,122]. Both compounds selectively inhibit cell growth and promote growth arrest of UM cells harboring oncogenic Gαq/11, as well as oncogenic cysteinyl leukotriene receptor 2 (CysLT2R129Q) [93,95,118–122]. FR, and likely YM, target both primary and metastatic cells from UM tumors [121]. YM and FR selectively inhibit the essential oncogenic signaling of Gαq/11 mutant UM cells. Treatment of UM cells with these Gq/11 inhibitors abolishes MAPK signaling, suppresses Akt activation, prevents YAP localization to the nucleus, and represses FAK activation [93,95,118–122].

Class one UM cells (wild-type for BAP1) begin to express melan-A at the plasma membrane and gain pigmentation when treated with low nanomolar concentrations of FR [118,119,121]. This suggests FR can induce a redifferentiation of these cancer cells, possibly by decreasing Gq/11 activity to a level closer to that of a normal melanocyte. It is believed that this FR-mediated redifferentiation is partly the result of restored function to the polycomb repressive complex 2, which plays a role in the differentiation of embryonic stem cells [119,121]. Concentrations of YM and FR at 100 nM and above selectively induce apoptosis and cell death of UM cells, as evidenced by increased caspase-3 and PARP cleavage, as well as an increased population of cells in the sub-G1 phase [95,118,119]. These Gq/11 inhibitors have shown great promise as potential therapeutics in cell-based assays, but are these results recapitulated in vivo?

To address this, there are some recent studies wherein UM mouse models were treated with YM and FR. The first of which showed that FR (0.5 mg/kg) treatment of severe combined immunodeficient (SCID) mice with subcutaneously grafted GαqQ209P UM cells resulted in 72% tumor growth inhibition after 14 days, whereas the growth of xenografts established from B-Raf mutant melanoma cells was unaffected [120]. A second recent study using subcutaneous UM tumor xenografts of Gα11Q209L and GαqQ209L UM cells, established in NOD-scid-gamma (NSG) mice, showed that FR inhibited the growth of UM tumors at 0.1 and 0.3 mg/kg, but had no effect on the growth of B-Raf mutant melanoma tumors [121]. However, UM tumors resumed growth 16 days after FR treatment was stopped, suggesting that FR only causes reversible, rather than durable, arrest or regression of UM tumors. ERK phosphorylation in xenograft tumors was only reduced by 30% compared to at least 85% observed in vitro, suggesting FR treatment does not completely suppress aberrant MAPK signaling in vivo. However, FR treatment does provide a therapeutic window in which tumors cells are targeted, while healthy cells maintain the correct physiological Gq/11 signaling. It is possible the observed incomplete inhibition of MAPK signaling is the result of a resistance or compensatory mechanism at work in these cells, as reverse-phase protein analysis showed an increase of HER3 and activated STAT3 upon FR treatment of UM cells in vitro [118]. Additionally, a recent study showed that YM, similar to FR, inhibited tumor formation in mice with xenografts of GαqQ209P UM cells [122]. Notably, it was observed during this study that YM does not durably suppress MAPK signaling of UM cells in vitro, and that MAPK signature genes begin to rebound after 24 h. This was similarly observed in tumors treated with YM ex vivo. However, a combination strategy of YM plus an MEK inhibitor was able to prevent reactivation and durably suppress MAPK in UM xenograft mice, while the combination also worked synergistically to inhibit tumor growth and promote tumor regression. Taken together, the current in vivo studies suggest Gq/11 inhibition as a viable therapeutic strategy to treat UM; however, to achieve durable arrest and regression of UM tumors, a combinatorial approach may be warranted.

5.4. Feasibility of Gq/11 Inhibitors as Potential Therapeutics

A recent study that sought to determine if YM and FR are fit for translation, and provides a solid basis for considering future in vivo investigations utilizing YM and FR [123]. It was determined that both YM and FR have high chemical stability under physiological...
conditions, and both are high clearance compounds in human liver microsomes. However, YM is more stable than FR in human liver microsomes, with short half-lives of 27.3 min and 8.1 min, respectively. Due to the high clearance rate of these compounds, they may not be suitable for systemic application. Importantly, in vivo studies showed that both compounds are only marginally able to cross the blood-brain barrier. However, local administration of these compounds will be preferred, since systemic application can be expected to block \(G_{q/11}\) signaling throughout the body. In this regard, the Blumer group determined a LD\(_{50}\) of approximately 0.6 mg/kg FR in NSG mice and showed that FR delivered at tolerable doses did not significantly affect heart rate, liver function, or hematopoiesis in xenograft UM models [121].

6. Discussion

Uveal melanomas are divided into class one (low metastatic risk) and class two (high metastatic risk) based on gene expression profiling [124]. While almost all UM patients have aberrations in the \(G_{q/11}\) pathway, particularly in the Goq_{11} proteins, these mutations occur early in tumorigenesis and are not correlated with molecular class or metastasis [31,125]. Class two tumors are strongly associated with an additional BAP1 mutation or deletion that occurs after Goq_{11} mutation [5]. This additional mutation increases the metastatic potential of UM, but aberrant Goq_{11} signaling remains as the main driver of tumorigenesis. Recently, the Blumer group has shown that both class one and class two tumor growth is inhibited by Goq_{11} inhibition by FR in UM xenografts [121]. This further strengthens the idea that targeting oncogenic Goq_{11} can be a viable therapeutic strategy in treating all subtypes of UM. Targeting oncogenic Goq_{11} has the additional benefit, over current monotherapy strategies, of inhibiting the multiple signaling networks downstream of Goq_{11}.

While Goq_{11} inhibitors show promise as future therapeutic options, their potential use presents a risk of adverse effects, as they act on both mutated and wild-type Goq_{11} proteins, which are ubiquitously expressed and have important physiological functions [126–129]. Clearly, compounds that can selectively target mutationally activated Goq_{11} over wild-type Goq_{11} would be ideal as therapeutic agents, but these do not currently exist. However, a growing body of work investigating the important moieties of YM and FR at the molecular level and how these compounds interact with Goq_{11}, provides valuable insight into the possible synthesis of such a compound. In an effort to synthesize YM, a few simplified YM analogs were synthesized based on the motifs of YM that are thought to be important in maintaining the compound’s stability and making contact with the Goq protein [130,131]. Its successful synthesis, in 2016, led to the production of many additional analogs used to probe the structure–activity relationship of YM, by modification of key structural elements of the compound [103,116,132,133]. However, all the analogs are less potent than YM, and it has become clear that even small structural changes result in reduced affinity for Goq. Many simplified analogs of FR have also been reported, and while a few selectively inhibit Goq_{11} at a comparable potency to FR, most have failed to inhibit Goq_{11}, and none have surpassed the biological activity of FR [116,134,135].

At present, the chemical and synthetic approaches to synthesizing YM and FR have low yields and very complex procedures. Purification of the compounds is the only way to obtain substantial quantities of YM and FR but is time consuming. However, having a method of chemical synthesis provides an avenue to rationally modify these compounds, determine crucial moieties for Goq_{11} inhibition, and possibly design compounds that may be able to more specifically target the oncogenic mutant Goq_{11}. Some have taken to using biosynthesis methods of creating new YM/FR analogs [136], while others are utilizing feature-based molecular networking techniques to identify new FR analogs produced by other bacterial strains [135,137]. A recent study using tritium-labelled YM and FR compounds in a high throughput competition binding assay discovered novel Goq inhibitors, which inhibited Goq signaling in recombinant cells and primary murine brown adipocytes, resulting in enhanced differentiation, albeit with significantly less potency than FR [117]. Moreover, the group that first synthesized YM and FR has recently reported a new Goq_{11}
inhibitor, GQ127, to be a potent, stable, and safe small molecule. It exhibits good $G_{q/11}$ protein inhibition and antitumor potency in vitro, and significantly inhibits in vivo tumor growth of UM cells [138]. While GQ127 requires significantly higher concentrations compared to YM and FR to observe similar effects on UM cell signaling and tumor growth, it is easily synthesized, displays high oral bioavailability, and shows no obvious side effects in mice. Therefore, it may be an additional structure to build upon for future UM drugs that target $G_{q/11}$.

7. Conclusions

Uveal melanoma is a rare melanoma that is biologically distinct from cutaneous melanoma and cannot be treated in a similar manner in the clinic. Despite a high level of success in treating primary UM locally, 36–50% of patients will eventually develop metastasis. To this point, the metastatic disease remains uncurable, and outcomes for patients with UM metastasis are poor [17]. Single agents that target signaling pathways downstream of mutated $G_{q/11}$ are not effective, and there is a desperate need for better treatment options. Combinational therapies that co-target multiple pathways are being investigated. The emergence of the $G_{q/11}$ inhibitors YM-254890 and FR900359, and their recent success in treating UM in preclinical studies, suggests that direct inhibition of oncogenic $G_{q/11}$ may be a viable approach, or at least provide a therapeutic window to treat the disease more effectively with an additional drug, such as an MEK inhibitor or an inhibitor of survival signals from the liver microenvironment. However, these $G_{q/11}$ inhibitors act on both mutated and wild-type $G_{q/11}$ proteins, which raises safety concerns, as $G_{q/11}$ is ubiquitously expressed and has a number of important physiological roles [126–129]. A local delivery system would be most advantageous, especially one that is able to target the liver, as it is likely that micrometastasis has already formed by the time of initial diagnosis. As we improve our understanding of how these compounds function and interact with $G_{q/11}$, the development of a compound that specifically targets the activated mutant $G_{q/11}$ may one day be possible.

Author Contributions: D.L., writing—original draft and editing; J.L.B., writing—review and editing. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Dr. Ralph and Marian Falk Medical Research Trust Bank of America, N.A., Trustee and National Institutes of Health awards P01 HL114471 (to J. Benovic) and F31 CA225064 (to D. Lapadula).

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Weis, E.; Shah, C.P.; Lajous, M.; Shields, J.A.; Shields, C.L. The association between host susceptibility factors and uveal melanoma: A meta-analysis. Arch. Ophthalmol. 2006, 124, 54–60. [CrossRef]
2. Shah, C.P.; Weis, E.; Lajous, M.; Shields, J.A.; Shields, C.L. Intermittent and chronic ultraviolet light exposure and uveal melanoma: A meta-analysis. Ophthalmology 2005, 112, 1599–1607. [CrossRef]
3. Shields, C.L.; Kaliki, S.; Livesey, M.; Walker, B.; Garoon, R.; Bucc, M.; Feinstein, E.; Pesch, A.; Gonzalez, C.; Lally, S.E.; et al. Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis: Analysis of 7872 consecutive eyes. JAMA Ophthalmol. 2013, 131, 993–1003. [CrossRef] [PubMed]
4. Hammer, H.; Oláh, J.; Tóth-Molnár, E. Dysplastic nevi are a risk factor for uveal melanoma. Eur. J. Ophthalmol. 1996, 6, 472–474. [CrossRef] [PubMed]
5. Harbour, J.W.; Onken, M.D.; Roberson, E.D.; Duan, S.; Cao, L.; Worley, L.A.; Council, M.L.; Matatall, K.A.; Helms, C.; Bowcock, A.M. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010, 330, 1410–1413. [CrossRef] [PubMed]
6. Singh, A.D.; Bergman, L.; Seregard, S. Uveal melanoma: Epidemiologic aspects. Ophthalmol Clin N. Am. 2005, 18, 75–84. [CrossRef] [PubMed]
7. Arnesen, K. The neural crest origin of uveal melanomas. Int. Ophthalmol. 1985, 7, 143–147. [CrossRef] [PubMed]
8. Damato, B. Ocular treatment of choroidal melanoma in relation to the prevention of metastatic death-A personal view. Prog. Retin. Eye Res. 2018, 66, 187–199. [CrossRef]
9. Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch. Ophthalmol. 2001, 119, 670–676. [CrossRef] [PubMed]

10. Kujala, E.; Mäkitie, T.; Kivelä, T. Very long-term prognosis of patients with malignant uveal melanoma. Investig. Ophthalmol. Vis. Sci. 2003, 44, 4651–4659. [CrossRef]

11. Diener-West, M.; Reynolds, S.M.; Agugliaro, D.J.; Caldwell, R.; Cumming, K.; Earle, J.D.; Hawkins, B.S.; Hayman, J.A.; Jaiyesimi, I.; Jampol, L.M.; et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch. Ophthalmol. 2005, 123, 1639–1643. [PubMed]

12. Eskelin, S.; Pyrhönen, S.; Summanen, P.; Hakka-Kemppinen, M.; Kivelä, T. Tumor doubling times in metastatic malignant melanoma of the uvea: Tumor progression before and after treatment. Ophthalmology 2000, 107, 1443–1449. [CrossRef]

13. Callejo, S.A.; Antecka, E.; Blanco, P.L.; Edelstein, C.; Burnier, M.N. Identification of circulating malignant cells and its correlation with prognosis and treatment in uveal melanoma. A prospective longitudinal study. Eye 2007, 21, 752–759. [CrossRef] [PubMed]

14. OssowskI, L.; Aguirre-Ghiso, J.A. Dormancy of metastatic melanoma. Pigment Cell Melanoma Res. 2010, 23, 41–56. [CrossRef]

15. Singh, A.D.; Turell, M.E.; Topham, A.K. Uveal melanoma: Trends in incidence, treatment, and survival. Ophthalmology 2011, 118, 1881–1885. [CrossRef]

16. Park, J.J.; Diefenbach, R.J.; Joshua, A.M.; Kefford, R.F.; Carlino, M.S.; Rizos, H. Oncogenic signaling in uveal melanoma. Cancer Treat. Rev. 2012, 38, 459–469. [CrossRef]

17. Yang, J.; Manson, D.K.; Marr, B.P.; Carvajal, R.D. Treatment of uveal melanoma: Where are we now? Ther. Adv. Med. Oncol. 2018, 10, 1758841818751775. [CrossRef]

18. Callejo, S.A.; Antecka, E.; Blanco, P.L.; Edelstein, C.; Burnier, M.N. Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye 2007, 21, 752–759. [CrossRef] [PubMed]

19. Diener-West, M.; Reynolds, S.M.; Agugliaro, D.J.; Caldwell, R.; Cumming, K.; Earle, J.D.; Hawkins, B.S.; Hayman, J.A.; Jaiyesimi, I.; Jampol, L.M.; et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch. Ophthalmol. 2005, 123, 1639–1643. [PubMed]

20. Spagnolo, F.; Caltabiano, G.; Queirolo, P. Uveal melanoma. Cancer Treat. Rev. 2012, 38, 459–469. [CrossRef]

21. Spagnolo, F.; Grosso, M.; Picasso, V.; Tornari, E.; Pesce, M.; Queirolo, P. Treatment of metastatic uveal melanoma with intravenous fotemustine. Melanoma Res. 2013, 23, 196–198. [CrossRef]

22. Augsburger, J.J.; Corrêa, Z.M.; Shaikh, A.H. Effectiveness of treatments for metastatic uveal melanoma. Am. J. Ophthalmol. 2009, 148, 119–127. [CrossRef]

23. Schmittel, A.; Schmidt-Hieber, M.; Martus, P.; Bechrakis, N.E.; Schuster, R.; Siehl, J.M.; Foerster, M.H.; Thiel, E.; Keilholz, U. A landscape of driver mutations in melanoma. Cell 2012, 150, 251–263. [CrossRef]

24. Homsi, J.; Bedikian, A.Y.; Papadopoulos, N.E.; Kim, K.B.; Hwu, W.-J.; Mahoney, S.L.; Hwu, P. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. Melanoma Res. 2010, 20, 507–510. [CrossRef]

25. Kelderman, S.; van der Kooij, M.K.; van den Eertwegh, A.J.M.; Soetekouw, P.M.M.B.; Jansen, R.L.H.; van den Brom, R.R.H.; Jampol, L.M.; et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch. Ophthalmol. 2005, 123, 1639–1643. [PubMed]

26. Heppt, M.V.; Steeb, T.; Schlager, J.G.; Rosumeck, S.; Dressler, C.; Ruzicka, T.; Nast, A.; Berking, C. Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review. Cancer Treat. Rev. 2017, 60, 44–52. [CrossRef]

27. Onken, M.D.; Worley, L.A.; Long, M.D.; Duan, S.; Council, M.L.; Bowcock, A.M.; Harbour, J.W. Oncogenic mutations in GNAQ occur early in uveal melanoma. Investig. Ophthalmol. Vis. Sci. 2008, 49, 5230–5234. [CrossRef]

28. Mignard, C.; Deschamps Huvier, A.; Gillibert, A.; Dutriaux, A.; Khammari, A.; Avril, M.-F.; Kramkimel, N.; Martoré, L.; Marcant, P.; et al. Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma. Ann. Oncol. 2004, 15, 705–710. [CrossRef] [PubMed]

29. Callejo, S.A.; Antecka, E.; Blanco, P.L.; Edelstein, C.; Burnier, M.N. Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye 2007, 21, 752–759. [CrossRef] [PubMed]

30. OssowskI, L.; Aguirre-Ghiso, J.A. Dormancy of metastatic melanoma. Pigment Cell Melanoma Res. 2010, 23, 41–56. [CrossRef]

31. Onken, M.D.; Worley, L.A.; Long, M.D.; Duan, S.; Council, M.L.; Bowcock, A.M.; Harbour, J.W. Oncogenic mutations in GNAQ occur early in uveal melanoma. Investig. Ophthalmol. Vis. Sci. 2008, 49, 5230–5234. [CrossRef]

32. Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.; Bottomley, W.; et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417, 949–954. [CrossRef]

33. Schmittel, A.; Schmidt-Hieber, M.; Martus, P.; Bechrakis, N.E.; Schuster, R.; Siehl, J.M.; Foerster, M.H.; Thiel, E.; Keilholz, U. A randomized phase II trial of gemicitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann. Oncol. 2006, 17, 1826–1829. [CrossRef]

34. Homsi, J.; Bedikian, A.Y.; Papadopoulos, N.E.; Kim, K.B.; Hwu, W.-J.; Mahoney, S.L.; Hwu, P. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. Melanoma Res. 2010, 20, 507–510. [CrossRef]

35. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 2015, 161, 1681–1696. [CrossRef]
36. Johansson, P.; Aoude, L.G.; Wadt, K.; Glasson, W.J.; Warrier, S.K.; Hewitt, A.W.; Kiiilgaard, J.F.; Heegaard, S.; Isaacs, T.; Franchina, M.; et al. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. *Oncotarget* 2016, 7, 4624–4631. [CrossRef]

37. Furney, S.J.; Pedersen, M.; Gentien, D.; Dumont, A.G.; Rapinat, A.; Desjardins, L.; Turajlic, S.; Piperno-Neumann, S.; de la Grange, P.; Roman-Roman, S.; et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. *Cancer Discov.* 2013, 3, 1122–1129. [CrossRef]

38. Van Raamsdonk, C.D.; Bezrookove, V.; Green, G.; Bauer, J.; Gaugler, L.; O’Brien, J.M.; Simpson, E.M.; Barsh, G.S.; Bastian, B.C. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. *Nature* 2009, 457, 599–602. [CrossRef]

39. Van Raamsdonk, C.D.; Griewank, K.G.; Crosby, M.B.; Garrido, M.C.; Vemula, S.; Wiesner, T.; Obaenauf, A.C.; Wackernagel, W.; Green, G.; Bourier, N.; et al. Mutations in GNA11 in uveal melanoma. *N. Engl. J. Med.* 2010, 363, 2191–2199. [CrossRef]

40. Yu, F.-X.; Luo, J.; Mo, J.-S.; Liu, G.; Kim, Y.C.; Meng, Z.; Zhao, L.; Peyman, G.; Ouyang, H.; Jiang, W.; et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. *Cancer Cell* 2014, 25, 822–830. [CrossRef]

41. Feng, X.; Degese, M.S.; Iglesias-Bartolome, R.; Vaque, J.P.; Molinolo, A.A.; Rodrigues, M.; Zaidi, M.R.; Ksander, B.R.; Merlino, G.; Sodhi, A.; et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. *Cancer Cell* 2014, 25, 822–830. [CrossRef]

42. Moore, A.R.; Ceraudo, E.; Sher, J.J.; Guan, Y.; Shoushtari, A.N.; Chang, M.T.; Zhang, J.Q.; Walczak, E.G.; Kazmi, M.A.; Taylor, B.S.; et al. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. *Nat. Genet.* 2016, 48, 675–680. [CrossRef] [PubMed] [CrossRef]

43. Ceraudo, E.; Horioka, M.; Mattheisen, J.M.; Hitchman, T.D.; Moore, A.R.; Kazmi, M.A.; Chi, P.; Chen, Y.; Sakmar, T.P.; Huber, T. Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling. *J. Biol. Chem.* 2021, 296, 100163. [CrossRef]

44. Offermanns, S. G-proteins as transducers in transmembrane signalling. *Prog. Biophys. Mol. Biol.* 2003, 83, 101–130. [CrossRef]

45. Johnston, C.A.; Siderovski, D.P. Receptor-mediated activation of heterotrimeric G-proteins: Current structural insights. *Mol. Pharmacol.* 2007, 72, 219–230. [CrossRef]

46. Milligan, G.; Kostenis, E. Heterotrimeric G-proteins: A short history. *Br. J. Pharmacol.* 2006, 147 (Suppl. 1), S46–S55. [CrossRef]

47. Oldham, W.M.; Hamm, H.E. Heterotrimeric G protein activation by G-protein-coupled receptors. *Nat. Rev. Mol. Cell Biol.* 2008, 9, 60–71. [CrossRef]

48. Yoo, J.H.; Shi, D.S.; Grossmann, A.H.; Sorensen, L.K.; Tong, Z.; Mleynek, T.M.; Rogers, A.; Zhu, W.; Richards, J.R.; Winter, J.M.; et al. ARF6 Is an Actionable Node that Orchestrates Oncogetic GNAQ Signaling in Uveal Melanoma. *Cancer Cell* 2016, 29, 889–904. [CrossRef]

49. Wu, D.Q.; Lee, C.H.; Rhee, S.G.; Simon, M.I. Activation of phospholipase C by the alpha subunits of the Gq and G11 proteins in transfected Cos-7 cells. *J. Biol. Chem.* 1992, 267, 1811–1817. [CrossRef]

50. Ross, E.M.; Wilkie, T.M. GTPase-activating proteins for heterotrimeric G proteins: Regulators of G protein signaling (RGS) and RGS-like proteins. *Annu. Rev. Biochem.* 2000, 69, 795–827. [CrossRef]

51. Kimple, A.J.; Bosch, D.E.; Giguère, P.M.; Siderovski, D.P. Regulators of G-protein signaling and their Gα subtypes: Promises and challenges in their use as drug discovery targets. *Pharmacol. Rev.* 2011, 63, 728–749. [CrossRef]

52. O’Hayre, M.; Vaquerizo-Prado, J.; Kufareva, I.; Stawiski, E.W.; Handel, T.M.; Seshagiri, S.; Gutkind, J.S. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. *Nat. Rev. Cancer* 2013, 13, 412–424. [CrossRef]

53. Van Eps, N.; Preininger, A.M.; Alexander, N.; Kaya, A.I.; Meier, S.; Meiler, J.; Hamm, H.E.; Hubbell, W.L. Interaction of a G protein with an activated receptor opens the interdomain interface in the alpha subunit. *J. Biol. Chem.* 1994, 269, 9828–9831. [CrossRef]

54. Kleuss, C.; Raw, A.S.; Lee, E.; Sprang, S.R.; Gilman, A.G. Mechanism of GTP hydrolysis by G-protein alpha subunits. *Proc. Natl. Acad. Sci. USA* 1994, 91, 9828–9831. [CrossRef]

55. Takasaki, J.; Saito, T.; Taniguchi, M.; Kawasaki, T.; Moritani, Y.; Hayashi, K.; Kobori, M. A novel Galphaq/11-selective inhibitor. *J. Biol. Chem.* 2004, 279, 47438–47445. [CrossRef]

56. Weber, A.; Hengge, U.R.; Urbanik, D.; Markwart, A.; Mirmodhamsaehg, A.; Reichel, M.B.; Wittekind, C.; Wiedemann, P.; Tannapfel, A. Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. *Lab. Invest.* 2003, 83, 1771–1776. [CrossRef] [PubMed]

57. Zuidervaart, W.; van Nieuwpoort, F.; Stark, M.; Dijkman, R.; Packer, L.; Borgstein, A.M.; Pavey, S.; van der Velden, P.; Out, C.; Jager, M.J.; et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. *Br. J. Cancer* 2005, 92, 2032–2038. [CrossRef]

58. Edmunds, S.C.; Cree, I.A.; Di Niccolantonio, F.; Hungerford, J.L.; Hurren, J.S.; Kelsell, D.P. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. *Br. J. Cancer* 2003, 88, 1403–1405. [CrossRef]

59. Vaqué, J.P.; Dorsam, R.T.; Feng, X.; Iglesias-Bartolome, R.; Forsthoefel, D.J.; Chen, Q.; Debant, A.; Seeger, M.A.; Ksander, B.R.; Teramoto, H.; et al. A genome-wide RNAi screen reveals a trio-regulated Rho GTPase circuitry transducing mitogenic signals initiated by G protein-coupled receptors. *Mol. Cell* 2013, 49, 94–108. [CrossRef]

60. Babchia, N.; Calipet, A.; Mouriaux, F.; Fausset, A.-M.; Mascarelli, F. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: Interaction with B-Raf/ERK. *Investig. Ophthalmol. Vis. Sci.* 2010, 51, 421–429. [CrossRef]
61. Chua, V.; Lapadula, D.; Randolph, C.; Benovic, J.L.; Wedegaertner, P.B.; Aplin, A.E. Dysregulated GPCR signaling and therapeutic options in uveal melanoma. *Mol. Cancer Res.* **2017**, *15*, 501–506. [CrossRef] [PubMed]

62. Wu, X.; Li, J.; Zhu, M.; Fletcher, J.A.; Hodi, F.S. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-kB pathways. *Mol. Cancer Ther.* **2012**, *11*, 1905–1914. [CrossRef]

63. Piperno-Neumann, S.; Kapiteijn, E.; Larkin, J.M.G.; Carvajal, R.D.; Luke, J.J.; Seifert, H.; Roosen, I.; Zoubir, M.; Yang, L.; Choudhury, S.; et al. Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma. *J. Clin. Oncol.* **2014**, *32*, 9030. [CrossRef]

64. Chen, X.; Wu, Q.; Tan, L.; Porter, D.; Jager, M.J.; Emery, C.; Bastian, B.C. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. *Oncogene* **2014**, *33*, 4724–4734. [CrossRef]

65. Ambrosini, G.; Pratillas, C.A.; Qin, L.-X.; Tadi, M.; Surriga, O.; Carvajal, R.D.; Schwartz, G.K. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance. *Clin. Cancer Res.* **2012**, *18*, 3552–3561. [CrossRef]

66. Carvajal, R.D.; Piperno-Neumann, S.; Kapiteijn, E.; Chapman, P.B.; Frank, S.; Joshua, A.M.; Piulats, J.M.; Wolter, P.; Cocquyt, V.; Chmielowski, B.; et al. Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: A phase III, multicenter, randomized trial (SUMIT). *J. Clin. Oncol.* **2018**, *36*, 1232–1239. [CrossRef]

67. Adjei, A.A.; LoRusso, P.; Ribas, A.; Somas, J.J.; Pavlick, A.C.; D’Y. Zhou, X.; Gangolli, E.A.; Walker, R.M.; Kneissl, M.; et al. Phase I, dose-escalation study of the investigational drug TAK-773, an oral MEK inhibitor, in patients (pts) with advanced solid tumors. *JCO* **2013**, *31*, 2528. [CrossRef]

68. Carvajal, R.D.; Piperno-Neumann, S.; Kapiteijn, E.; Chapman, P.B.; Frank, S.; Joshua, A.M.; Piulats, J.M.; Wolter, P.; Cocquyt, V.; Chmielowski, B.; et al. Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: A phase III, multicenter, randomized trial (SUMIT). *J. Clin. Oncol.* **2018**, *36*, 1232–1239. [CrossRef]

69. Kirkwood, J.M.; Bastholt, L.; Robert, C.; Somas, J.J.; Larkin, J.; Hersey, P.; Middleton, M.; Cantarini, M.; Zazulina, V.; Kemsley, K.; et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. *Clin. Cancer Res.* **2012**, *18*, 555–567. [CrossRef]

70. Shoushtari, A.N.; Kudchadkar, R.R.; Panageas, K.; Murthy, R.K.; Jung, M.; Shah, R.; O’Donnell, B.; Khawaja, T.T.; Shames, Y.; Prempeh-Keteku, N.A.; et al. A randomized phase 2 study of trametinib with or without GSK2141795 in patients with metastatic uveal melanoma. *J. Clin. Oncol.* **2016**, *34*, 9511. [CrossRef]

71. Falchook, G.S.; Lewis, K.D.; Infante, J.R.; Gordon, M.S.; Vogelzang, N.J.; DeMarini, D.J.; Sun, P.; Moy, C.; Szabo, S.A.; Roadcap, L.T.; et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: A phase 1 dose-escalation trial. *Lancet Oncol.* **2012**, *13*, 782–789. [CrossRef]

72. Steeb, T.; Wessely, A.; Ruzicka, T.; Hepp, M.V.; Berking, C. How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma. *Eur. J. Cancer* **2018**, *103*, 41–51. [CrossRef]

73. Cheng, H.; Chua, V.; Liao, C.; Purwin, T.J.; Terai, M.; Kageyama, K.; Davies, M.A.; Sato, T.; Aplin, A.E. Co-targeting HGF/CMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. *Mol. Cancer Ther.* **2017**, *16*, 516–528. [CrossRef]

74. Cheng, H.; Terai, M.; Kageyama, K.; Ozaki, S.; McCue, P.A.; Sato, T.; Aplin, A.E. Paracrine effect of NRG1 and HGF drives MAPK pathway activation in GNAQ mutant uveal melanoma. *Cancer Res.* **2015**, *75*, 2377–2447. [CrossRef]

75. Decaudin, D.; El Botty, R.; D’Olio, B.; Massonnet, G.; Fleury, J.; Naguez, A.; Raymond, C.; Davies, E.; Smith, A.; Wilson, J.; et al. Selumetinib-based therapy in uveal melanoma patient-derived xenografts. *OncoTarget* **2018**, *9*, 21674–21686. [CrossRef]

76. Truong, A.; Yoo, J.H.; Scherer, M.T.; Sanchez, J.M.S.; Dale, K.J.; Kinsey, C.G.; Richards, J.R.; Shin, D.; Ghazi, P.C.; Onken, M.D.; et al. Chloroquine Sensitizes GNAQ/11-mutated Melanoma to MEK1/2 Inhibition. *Clin. Cancer Res.* **2020**, *26*, 6374–6386. [CrossRef]

77. Chen, X.; Wu, Q.; Depeille, P.; Chen, P.; Thornton, S.; Kalirai, H.; Coupland, S.E.; Roose, J.P.; Bastian, B.C. Rasgrf3 mediates MAPK pathway activation in GNAQ mutant uveal melanoma. *Cancer Cell* **2017**, *31*, 685–696.e6. [CrossRef]

78. Moore, A.R.; Ran, L.; Guan, Y.; Shen, J.J.; Hitchman, T.D.; Zhang, J.Q.; Hwang, C.; Walzak, E.G.; Shoushtari, A.N.; Monette, S.; et al. GNA11 Q209L mouse model reveals RasGRP3 as an essential signaling node in uveal melanoma. *Cell Rep.* **2018**, *22*, 2455–2468. [CrossRef]

79. Khalili, J.S.; Yu, X.; Wang, J.; Hayes, B.C.; Davies, M.A.; Lizee, G.; Esmaeili, B.; Woodman, S.E. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. *Clin. Cancer Res.* **2012**, *18*, 4345–4355. [CrossRef]

80. Musi, E.; Ambrosini, G.; de Stanchina, E.; Schwartz, G.K. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells. *Mol. Cancer Ther.* **2014**, *13*, 1044–1053. [CrossRef]

81. Ambrosini, G.; Musi, E.; Ho, A.L.; de Stanchina, E.; Schwartz, G.K. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. *Mol. Cancer Ther.* **2013**, *12*, 768–776. [CrossRef]

82. Shoushtari, A.N.; Ong, L.T.; Schoeder, H.; Singh-Kandah, S.; Abbate, K.T.; Postow, M.A.; Callahan, M.K.; Wolchok, J.; Chapman, P.B.; Panageas, K.S.; et al. A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma. *Melanoma Res.* **2016**, *26*, 272–277. [CrossRef]
83. Amirouche-Angelozzi, N.; Frisch-Dit-Leitze, E.; Carita, G.; Dahmani, A.; Raymondie, C.; Liot, G.; Gentien, D.; Némati, F.; Decaudin, D.; Roman-Roman, S.; et al. The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma. *Oncoarget 2016*, 7, 23633–23646. [CrossRef]

84. Carita, G.; Frisch-Dit-Leitze, E.; Dahmani, A.; Raymondie, C.; Cassoux, N.; Piperno-Neumann, S.; Némati, F.; Laurent, C.; de Koning, L.; Hallilovic, E.; et al. Dual inhibition of protein kinase C and p53-MDM2 or FKC and mTORC1 are novel efficient therapeutic approaches for uveal melano. *Oncoarget 2016*, 7, 33542–33556. [CrossRef]

85. Zhang, K.; Qi, H.-X.; Hu, Z.-M.; Chang, Y.-N.; Shi, Z.-M.; Han, X.-H.; Han, Y.-W.; Zhang, R.-X.; Zhang, Z.; Chen, T.; et al. YAP and TAZ take center stage in cancer. *Biochemistry 2015*, 54, 6555–6666. [CrossRef]

86. Liu-Chittenden, Y.; Huang, B.; Shim, J.S.; Chen, Q.; Lee, S.J.; Anders, R.A.; Liu, J.O.; Pan, D. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. *Genes Dev. 2012*, 26, 1300–1305. [CrossRef]

87. Pan, D. The Hippo signaling pathway in development and cancer. *Dev. Cell 2010*, 19, 491–505. [CrossRef]

88. Ramos, A.; Camargo, F.D. The Hippo signaling pathway and stem cell biology. *Trends Cell Biol. 2012*, 22, 339–346. [CrossRef]

89. Yu, F.-X.; Guan, K.-L. The Hippo pathway: Regulators and regulations. *Genes Dev. 2013*, 27, 355–371. [CrossRef]

90. Lyubasvyuk, V.; Ouyang, H.; Yu, F.-X.; Guan, K.-L.; Zhang, K. YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations. *Mol. Cell. Oncol. 2015*, 2, e970957. [CrossRef]

91. Kim, Y.J.; Lee, S.C.; Kim, S.E.; Kim, S.K.; Lee, C.S. YAP Activity is Not Associated with Survival of Uveal Melanoma Patients and Cell Lines. *Sci. Rep. 2020*, 10, 6209. [CrossRef]

92. Brouwer, N.J.; Konstantinou, E.K.; Gragoudas, E.S.; Marinkovic, M.; Luyten, G.P.M.; Kim, I.K.; Jager, M.J.; Vavvas, D.G. Targeting the YAP/TAZ pathway in uveal and conjunctival melanoma with verteporfin. *Investig. Ophthalmol. Vis. Sci. 2021*, 62, 3. [CrossRef]

93. Feng, X.; Arang, N.; Rigiracciolo, D.C.; Lee, J.S.; Yeerna, H.; Wang, Z.; Lubrano, S.; Kishore, A.; Pachter, J.A.; König, G.M.; et al. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK. *Cancer Cell 2019*, 35, 457–472.e5. [CrossRef]

94. Paradis, J.S.; Acosta, M.; Saddawi-Konefka, R.; Kishore, A.; Gomes, F.; Arang, N.; Tiago, M.; Coma, S.; Lubrano, S.; Wu, X.; et al. Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Medicine for GNAQ-Driven Uveal Melanoma. *Clin. Cancer Res. 2021*, 27, 3190–3200. [CrossRef]

95. Ma, J.; Weng, L.; Bastian, B.C.; Chen, X. Functional characterization of uveal melanoma oncogenes. *Oncogene 2021*, 40, 806–820. [CrossRef]

96. Shain, A.H.; Bagger, M.M.; Yu, R.; Chang, D.; Liu, S.; Vemula, S.; Weier, J.F.; Wadat, K.; Heegaard, S.; Bastian, B.C.; et al. The genetic evolution of metastatic uveal melanoma. *Nat. Genet. 2019*, 51, 1123–1130. [CrossRef]

97. Zhang, H.; Nielsen, A.L.; Strømgaard, K. Recent achievements in developing selective Gq inhibitors. *Med. Res. Rev. 2020*, 40, 135–157. [CrossRef]

98. Kostenis, E.; Pfeil, E.M.; Annala, S. Heterotrimeric Gq proteins as therapeutic targets? *J. Biol. Chem. 2020*, 295, 5206–5215. [CrossRef]

99. Taniguchi, M.; Nagai, K.; Arao, N.; Kawasaki, T.; Saito, T.; Moritani, Y.; Takasaki, J.; Hayashi, K.; Fujita, S.; Suzuki, K.; et al. YM-254890, a novel platelet aggregation inhibitor produced by Chromobacterium sp. QS3666. *J. Antibiot. 2003*, 56, 358–363. [CrossRef]

100. Uemura, T.; Kawasaki, T.; Taniguchi, M.; Moritani, Y.; Hayashi, K.; Saito, T.; Takasaki, J.; Uchida, W.; Miyata, K. Biological properties of a specific Galpha q/11 inhibitor, YM-254890, on platelet functions and thrombus formation under high-shear stress. *Br. J. Pharmacol. 2006*, 148, 61–69. [CrossRef]

101. Kawasaki, T.; Taniguchi, M.; Moritani, Y.; Uemura, T.; Shigenaga, T.; Takamatsu, H.; Hayashi, K.; Takasaki, J.; Saito, T.; Nagai, K. Pharmacological properties of YM-254890, a specific Galpha q/11 inhibitor, on thrombosis and neointima formation in mice. *Thromb. Haemost. 2005*, 94, 184–192. [CrossRef]

102. Kawasaki, T.; Taniguchi, M.; Moritani, Y.; Hayashi, K.; Saito, T.; Takasaki, J.; Nagai, K.; Inagaki, O.; Shikama, H. Antithrombotic and thrombolytic efficacy of YM-254890, a G q/11 inhibitor, in a rat model of arterial thrombosis. *Thromb. Haemost. 2003*, 90, 406–413. [CrossRef] [PubMed]

103. Xiong, X.-F.; Zhang, H.; Underwood, C.R.; Harpse, K.; Gardella, T.J.; Wöldike, M.F.; Mannstadt, M.; Gloriam, D.E.; Bräuner-Osborne, H.; Strømgaard, K. Total synthesis and structure-activity relationship studies of a series of selective G protein inhibitors. *Nat. Chem. 2016*, 8, 1035–1041. [CrossRef]

104. Fujioka, M.; Koda, S.; Morimoto, Y.; Biemann, K. Structure of FR900359, a cyclic depsipeptide from Ardisia crenata s. *J. Org. Chem. 1988*, 53, 2820–2825. [CrossRef]

105. Carlier, A.; Fehr, L.; Pinto-Carbó, M.; Schäberle, T.; Reher, R.; Dessein, S.; König, G.; Eberl, L. The genome analysis of Ardisia crenata symbiosis reveals that secondary metabolism may be a key function of the *Ardisia crenata* leaf nodule symbiosis. *Environ. Microbiol. 2016*, 18, 2507–2522. [CrossRef] [PubMed]

106. Inamdar, V.; Patel, A.; Manne, B.K.; Dangelmaier, C.; Kunapuli, S.P. Characterization of UBO-QIC as a Gq agonist in platelets. *Platelets 2015*, 26, 771–778. [CrossRef]

107. Schräge, R.; Schmitz, A.-L.; Caffal, E.; Annala, S.; Kehraus, S.; Wenzel, D.; Büllesbach, K.M.; Bald, T.; Inoue, A.; Shinjo, Y.; et al. The experimental power of FR900359 to study Gq-regulated biological processes. *Nat. Commun. 2015*, 6, 10156. [CrossRef]

108. Zaima, K.; Deguchi, J.; Matsuno, Y.; Kanda, T.; Hirasawa, Y.; Morita, H. Vasorelaxant effect of FR900359 from *Ardisia crenata* on rat aortic artery. *J. Nat. Med. 2013*, 67, 196–201. [CrossRef] [PubMed]
Cancers 2021, 13, 6195

109. Carr, R.; Koziol-White, C.; Zhang, J.; Lam, H.; An, S.S.; Tall, G.G.; Panettieri, R.A.; Benovic, J.L. Interdicting Gq Activation in Airway Disease by Receptor-Dependent and Receptor-Independent Mechanisms. Mol. Pharmacol. 2016, 89, 94–104. [CrossRef]

110. Gao, Z.-G.; Jacobson, K.A. On the selectivity of the Gaq inhibitor UBO-QIC: A comparison with the Gaq inhibitor pertussis toxin. Biochem. Pharmacol. 2016, 107, 59–66. [CrossRef]

111. Pistorius, D.; Buntin, K.; Bouquet, C.; Richard, E.; Weber, E.; Wollbrett, S. Toward the Selective Inhibition of G Proteins: Total Synthesis of a Simplified YM254890 Analog. Angew. Chem. Int. Ed. Engl. 2018, 57, 836–840. [CrossRef] [PubMed]

112. Pistorius, D.; Buntin, K.; Bouquet, C.; Richard, E.; Weber, E.; Wellbrett, S. Genetic Engineering of Chromobacterium vaccinii DSM 25150 for Improved Production of FR900359; ChemRxiv; Cambridge Open Engage: Cambridge, UK, 2021; This content is a preprint and has not been peer-reviewed. [CrossRef]

113. Nishimura, A.; Kitano, K.; Takasaki, J.; Taniguchi, M.; Mizuno, N.; Tago, K.; Hokoshima, T.; Itoh, H. Structural basis for the specific inhibition of heterotrimeric G protein by a small molecule. Proc. Natl. Acad. Sci. USA 2010, 107, 13666–13671. [CrossRef] [PubMed]

114. Malfacini, D.; Patt, J.; Annala, S.; Harpsøe, K.; Eryilmaz, F.; Reher, R.; Crüsemann, M.; Hanke, W.; Zhang, H.; Tietze, D.; et al. Rational design of a heterotrimeric G protein α subunit with artificial inhibitor sensitivity. J. Biol. Chem. 2019, 294, 5747–5758. [PubMed]

115. Zhang, H.; Nielsen, A.L.; Boesgaard, M.W.; Harpsøe, K.; Daly, N.L.; Xiong, X.-F.; Underwood, C.R.; Haugaard-Kedström, L.M.; Bräuner-Osborne, H.; Gloriam, D.E.; et al. Structure-activity relationship and conformational studies of the natural product cyclic depsipeptides YM-254890 and FR900359. Eur. J. Med. Chem. 2018, 156, 847–860. [CrossRef] [PubMed]

116. Usami, N.; Namasiyavam, V.; Rafiehi, M.; Voss, J.H.; Garg, J.; Schlegel, J.G.; Abdellahman, A.; Kehraus, S.; Reher, R.; Küppers, J.; et al. Cell-permeable high-affinity tracers for Gq proteins provide structural insights, reveal distinct binding kinetics and identify small molecule inhibitors. Br. J. Pharmacol. 2016, 177, 1898–1916. [CrossRef]

117. Lapadula, D.; Farias, E.; Randolph, C.E.; Purwin, T.J.; McGrath, D.; Charpentier, T.H.; Zhang, L.; Wu, S.; Terai, M.; Sato, T.; et al. Effects of oncogenic Gaq and G11 inhibition on uveal melanoma. Mol. Cancer Res. 2019, 17, 963–973. [CrossRef]

118. Onken, M.D.; Makepeace, C.M.; Kaltenbronn, K.M.; Kanai, S.M.; Todd, T.D.; Wang, S.; Broekelmann, T.J.; Rao, P.K.; Cooper, J.A.; Blumer, K.J. Targeting nucleotide exchange to inhibit constitutively active G protein α subunits in cancer cells. Sci. Signal. 2018, 11, 546. [PubMed]

119. Annala, S.; Feng, X.; Shridhar, N.; Eryilmaz, F.; Patt, J.; Yang, J.; Pfeil, E.M.; Cervantes-Villagrana, R.D.; Inoue, A.; Håberlein, F.; et al. Direct targeting of Gaq and G11 oncoproteins in cancer cells. Sci. Signal. 2019, 12, 573. [CrossRef]

120. Onken, M.D.; Makepeace, C.M.; Kaltenbronn, K.M.; Choi, J.; Hernandez-Aya, L.; Weilbaecher, K.N.; Piggott, K.D.; Rao, P.K.; Yuedo, C.M.; Dixon, A.J.; et al. Targeting primary and metastatic uveal melanoma with a Gprotein inhibitor. J. Biol. Chem. 2021, 296, 100403. [CrossRef]

121. Hitchman, T.D.; Baystok, G.; Ceraudo, E.; Moore, A.R.; Lee, C.; Jia, R.; Wang, N.; Pachai, M.R.; Shoushtari, A.N.; Francis, J.H.; et al. Combined inhibition of oncogenic Gaq and MEK enhances therapeutic efficacy in uveal melanoma. Br. J. Pharmacol. 2021, 27, 1497–1499. [CrossRef]

122. Schlegel, J.G.; Tahoun, M.; Seidinger, A.; Voss, J.H.; Kuschk, M.; Kehraus, S.; Schneider, M.; Matthey, M.; Fleischmann, B.K.; König, G.M.; et al. Macrocyclic Gq Protein Inhibitors FR900359 and/or YM-254890—Fit for Translation? ACS Pharmacol. Transl. Sci. 2021, 4, 888–897. [CrossRef] [PubMed]

123. Orken, M.D.; Worley, L.A.; Ehlers, J.P.; Harbour, J.W. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004, 64, 7205–7209. [CrossRef]

124. Bauer, J.; Kilic, E.; Vaarwater, J.; Bastian, B.C.; Garbe, C.; de Klein, A. Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br. J. Cancer 2009, 101, 813–815. [CrossRef]

125. Offermanns, S.; Hashimoto, K.; Watanabe, M.; Sun, W.; Kurihara, H.; Thompson, R.F.; Inoue, Y.; Kano, M.; Simon, M.I. Impaired motor coordination and persistent multiple climbing fiber innervation of cerebellar Purkinje cells in mice lacking Galphαq. Proc. Natl. Acad. Sci. USA 1997, 94, 14094–14099. [CrossRef]

126. Offermanns, S.; Zhao, L.P.; Gohla, A.; Barrott, K.; Simon, M.I.; Wilkie, T.M. Embryonic cardiomyocyte hypoplasia and craniofacial defects in G alpha q knockout mice. J. Biol. Chem. 1998, 273, 4304–4312. [PubMed]

127. Frederick, A.L.; Saborido, T.P.; Stanwood, G.D. Neurobehavioral phenotyping of Gaq knockout mice reveals impairments in motor functions and spatial working memory without changes in anxiety or behavioral despair. Front. Behav. Neurosci. 2012, 6, 29. [CrossRef] [PubMed]

128. Wiesner, K.; Kaiser, E.; Schröder, L.; Scholz, A.; Ruppenthal, S.; Reil, J.-C.; Backes, C.; Meese, E.; Meier, C.; Bogdanova, A.; et al. Cardiac remodeling in Gaq and G11 knockout mice. Int. J. Cardiol. 2016, 202, 836–845. [CrossRef] [PubMed]

129. Rensing, D.T.; Uppal, S.; Blumer, K.J.; Moeller, K.D. Toward the Selective Inhibition of G Proteins: Total Synthesis of a Simplified YM-254890 Analog. Org. Lett. 2015, 17, 2270–2273. [CrossRef]

130. Kaur, H.; Harris, P.W.R.; Little, P.J.; Brimble, M.A. Total synthesis of the cyclic depsipeptide YM-280193, a platelet aggregation inhibitor. Org. Lett. 2015, 17, 492–495. [CrossRef]
132. Zhang, H.; Xiong, X.-F.; Boesgaard, M.W.; Underwood, C.R.; Bräuner-Osborne, H.; Strømgaard, K. Structure-Activity Relationship Studies of the Cyclic Depsipeptide Natural Product YM-254890, Targeting the Gq Protein. *Chem. Med. Chem.* 2017, 12, 830–834. [CrossRef]

133. Xiong, X.-F.; Zhang, H.; Boesgaard, M.W.; Underwood, C.R.; Bräuner-Osborne, H.; Strømgaard, K. Structure-Activity Relationship Studies of the Natural Product Gq/11 Protein Inhibitor YM-254890. *Chem. Med. Chem.* 2019, 14, 865–870. [CrossRef] [PubMed]

134. Reher, R.; Kühl, T.; Annala, S.; Benkel, T.; Kaufmann, D.; Nubbenmeyer, B.; Odhiambo, J.P.; Heimer, P.; Bäuml, C.A.; Kehraus, S.; et al. Deciphering Specificity Determinants for FR900359-Derived Gq α Inhibitors Based on Computational and Structure-Activity Studies. *Chem. Med. Chem.* 2018, 13, 1634–1643. [CrossRef] [PubMed]

135. Reher, R.; Kuschak, M.; Heycke, N.; Annala, S.; Kehraus, S.; Dai, H.-F.; Müller, C.E.; Kostenis, E.; König, G.M.; Crüsemann, M. Applying molecular networking for the detection of natural sources and analogues of the selective Gq protein inhibitor FR900359. *J. Nat. Prod.* 2018, 81, 1628–1635. [CrossRef]

136. Hermes, C.; Richarz, R.; Wirtz, D.A.; Patt, J.; Hanke, W.; Kehraus, S.; Voß, J.H.; Küppers, J.; Ohbayashi, T.; Namasivayam, V.; et al. Thioesterase-mediated side chain transesterification generates potent Gq signaling inhibitor FR900359. *Nat. Commun.* 2021, 12, 144. [CrossRef]

137. Hanke, W.; Patt, J.; Alenfelder, J.; Voss, J.H.; Zdouc, M.M.; Kehraus, S.; Kim, J.B.; Gruijić, G.V.; Namasivayam, V.; Reher, R.; et al. Feature-Based Molecular Networking for the Targeted Identification of Gq-Inhibiting FR900359 Derivatives. *J. Nat. Prod.* 2021, 84, 1941–1953. [CrossRef] [PubMed]

138. Ge, Y.; Shi, S.; Deng, J.-J.; Chen, X.-P.; Song, Z.; Liu, L.; Lou, L.; Zhang, X.; Xiong, X.-F. Design, synthesis, and evaluation of small molecule Gaq/11 protein inhibitors for the treatment of uveal melanoma. *J. Med. Chem.* 2021, 64, 3131–3152. [CrossRef]